Genentech, Inc.

Constellation Pharmaceuticals, Inc.

Genetech, Inc.

Daniel J Burdick

Shumei Wang

Huifen Chen

Zachary Kevin Sweeney

Christopher G Nasveschuk

Anthony A Estrada

Brian K Albrecht

Bryan K Chan

Steven R Magnuson

Mark Stewart Chambers

Alexander M Taylor

Vickie Hsiao-Wei Tsui

Charles Baker-Glenn

Terry Crawford

Alexandre Cote

F Anthony Romero

Michael Charles Hewitt

Yong Tang

Steven F Bellon

Guiling Zhao

Daniel Shore

Les A Dakin

Yves LeBlanc

Wei Ey Li

Thomas Gadek

Robert A Lazarus

David A Oare

Daniel Kirchhofer

Martin Duplessis

Mark E Reynolds

Mark S Stanley

Yingnan Zhang

Maureen H Beresini

Nicholas Skelton

Janet L Gunzner-Toste

Mark Ultsch

James C Marsters

Charles Eigenbrot, Jr

John Quinn

Yves Leblanc

Kevin X Chen

Richard Pastor

Weiru Wang

Kwong Wah Lai

Jeremy M Murray

Anthony F Romero

Marc Adler

Janet Gunzner-Tate

Christopher G Nasveschuck

Kevin Chen

The invention provides PCSK9 inhibitors, compositions comprising the PCSK9 inhibitors, and methods of identifying and using the PCSK9 inhibitors.

Compositions and methods for treating cardiovascular disease

The present invention relates to compounds of formula (I): and to salts thereof, wherein R, R, R, and Rhave any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Therapeutic compounds and uses thereof

The invention relates to compounds of formula (I) and salts thereof: wherein R-Rhave any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

The present invention relates to compounds of formula (I): and to salts thereof, wherein R-Rhave any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

The present invention relates to compounds of formula (I): and to salts thereof, wherein R, R, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

Compounds having the formula I wherein Rand Rare as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders. 

Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors

Pyrazole compounds that are modulators of LRRK2, methods of making the compounds, and methods for using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Pyrazole aminopyrimidine derivatives as LRRK2 modulators

Aminopyrimidine derivatives as LRRK2 modulators

Compounds of the formula I: or pharmaceutically acceptable salts thereof,

Compounds of the formula I: or pharmaceutically acceptable salts thereof,wherein m, n. X, R, R, R, R, Rand Rare as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

Aminopyrimidine derivatives as LRRK2 inhibitors

The invention relates to novel compounds having formula (I)wherein Cy, X, Y, L and Rare as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.

LFA-1 antagonist compounds

Growing community of inventors

South San Francisco, CA, United States of America

Daniel J Burdick